Neuropsychiatric Impact of Androgen Deprivation Therapy in Patients with Prostate Cancer: Current Evidence and Recommendations for the Clinician
- PMID: 32690473
- DOI: 10.1016/j.euf.2020.05.014
Neuropsychiatric Impact of Androgen Deprivation Therapy in Patients with Prostate Cancer: Current Evidence and Recommendations for the Clinician
Abstract
Context: Although substantial literature examining the neuropsychiatric consequences of androgen deprivation therapy (ADT) exists, there are no clinical guidelines to inform providers about the specific risk of depression, suicide, and dementia for prostate cancer patients receiving chronic ADT.
Objective: To evaluate the strength of the evidence and interpret the literature describing the association between ADT and psychological outcomes in men with prostate cancer.
Evidence acquisition: NIH/NCBI PubMed database, EMBASE, and PsychINFO were searched for articles published indexed through December 16, 2019. Results from a total of 48 recent and highly relevant articles are summarized here.
Evidence synthesis: ADT increased the risk of depression (relative risk [RR] 1.51, p = 0.0002), which in turn magnifies the impact of ADT-related side effects on masculine identity. ADT may be associated with increased risk of cognitive impairment, including the risk of Alzheimer's dementia in American population-based cohorts and the risk of all-cause dementia in non-American cohorts (RR 1.45, p = 0.024). Statin use and higher levels of physical activity may be protective against ADT-associated dementia.
Conclusions: ADT increases the risk of worsening and incident depression, and may increase the risk of dementia in men with prostate cancer. Brief baseline mood and cognitive screening assessments, with re-evaluation at 6-12 mo is strongly recommended when initiating ADT. Patients exhibiting new or worsening symptoms of depression or dementia may benefit from referral for formal evaluation and possible treatment.
Patient summary: Patients initiating androgen deprivation therapy (ADT) should have brief baseline mood and cognitive screening assessments, with re-evaluation at least 6-12 mo after initiating therapy. All patients starting ADT should be counseled regarding possible neuropsychiatric side effects, and prescribers should counsel patients regarding the potential negative sexual side effects of antidepressant medications before prescribing them. Patients exhibiting new or worsening symptoms of depression or dementia may benefit from referral for formal evaluation and possible treatment.
Take home message: Androgen deprivation therapy (ADT) increases the risk of depression, which in turn magnifies the impact of ADT-related side effects on masculine identity and psychological distress in men with prostate cancer. ADT may be associated with an increased risk of cognitive impairment.
Keywords: Androgen deprivation therapy; Dementia; Depression; Neuropsychiatric; Prostate cancer.
Copyright © 2020 European Association of Urology. Published by Elsevier B.V. All rights reserved.
Similar articles
-
Androgen Deprivation Therapy and Mental Health: Impact on Depression and Cognition.Eur Urol Focus. 2020 Nov 15;6(6):1162-1164. doi: 10.1016/j.euf.2019.11.010. Epub 2020 Jan 3. Eur Urol Focus. 2020. PMID: 31911085 Review.
-
Risk of Dementia and Depression in Young and Middle-aged Men Presenting with Nonmetastatic Prostate Cancer Treated with Androgen Deprivation Therapy.Eur Urol Oncol. 2021 Feb;4(1):66-72. doi: 10.1016/j.euo.2019.08.003. Epub 2019 Oct 14. Eur Urol Oncol. 2021. PMID: 31624049
-
Effects of Androgen Deprivation Therapy on Pain Perception, Quality of Life, and Depression in Men With Prostate Cancer.J Pain Symptom Manage. 2018 Feb;55(2):307-317.e1. doi: 10.1016/j.jpainsymman.2017.09.017. Epub 2017 Sep 21. J Pain Symptom Manage. 2018. PMID: 28941963 Free PMC article.
-
Androgen deprivation therapy and depression in the prostate cancer patients: review of risk and pharmacological management.Aging Male. 2022 Dec;25(1):101-124. doi: 10.1080/13685538.2022.2053954. Aging Male. 2022. PMID: 35343371 Review.
-
Psychological effects of androgen-deprivation therapy on men with prostate cancer and their partners.Cancer. 2015 Dec 15;121(24):4286-99. doi: 10.1002/cncr.29672. Epub 2015 Sep 15. Cancer. 2015. PMID: 26372364 Review.
Cited by
-
Changes in Quality of Life and Sexual Function After Luteinizing Hormone-Releasing Hormone (LHRH) Agonists and Orchiectomy in Men With Metastatic Prostate Cancer: Results From a Randomized Trial.Cureus. 2024 Mar 11;16(3):e55934. doi: 10.7759/cureus.55934. eCollection 2024 Mar. Cureus. 2024. PMID: 38601370 Free PMC article.
-
A systematic review evaluating the effectiveness of exercise training on physical condition in prostate cancer patients undergoing androgen deprivation therapy.Transl Androl Urol. 2023 Aug 31;12(8):1336-1350. doi: 10.21037/tau-23-272. Epub 2023 Aug 4. Transl Androl Urol. 2023. PMID: 37680229 Free PMC article. Review.
-
How to Improve the Quality of Life of Patients with Prostate Cancer Treated with Hormone Therapy?Res Rep Urol. 2023 Jan 19;15:9-26. doi: 10.2147/RRU.S350793. eCollection 2023. Res Rep Urol. 2023. PMID: 36698681 Free PMC article. Review.
-
The role of testosterone, the androgen receptor, and hypothalamic-pituitary-gonadal axis in depression in ageing Men.Rev Endocr Metab Disord. 2022 Dec;23(6):1259-1273. doi: 10.1007/s11154-022-09767-0. Epub 2022 Nov 22. Rev Endocr Metab Disord. 2022. PMID: 36418656 Free PMC article. Review.
-
[Testosterone and Alzheimer's disease].Probl Endokrinol (Mosk). 2022 Jun 24;68(5):97-107. doi: 10.14341/probl13136. Probl Endokrinol (Mosk). 2022. PMID: 36337024 Free PMC article. Russian.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical